ClinicalTrials.gg
RecruitingNCT07947316Updated Nov 18, 2026

A RANDOMİZED CONTROLLED TRİAL COMPARİNG THE EFFECTİVENESS OF MYOFASCİAL RELEASE, LOW-LEVEL LASER THERAPY, AND PELOİD THERAPY İN PATİENTS DİAGNOSED WİTH MİLD TO MODERATE CARPAL TUNNEL SYNDROME

An interventional study of Low-Level Laser Therapy and Myofascial Release in Carpal Tunnel Syndrome (CTS), sponsored by Konya Beyhekim Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Konya Beyhekim Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2026, registered Nov 2026).
  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 130 studies in Carpal Tunnel Syndrome with a site in Turkey — 36 open to participants now, 41 under way, none of them phase 3. Carpal Tunnel Syndrome · Turkey.

Planned enrollment
16th of 82
88 · median 60
Started
2026
with 19 others
No phase
75 of 130
21 open now
Primary completion
2027-03
later than 34 of 40 live
Registered
130th of 130
by date
Lead sponsor
5 of 130
Konya Beyhekim Training and Research Hospital

Among the 130 studies in Carpal Tunnel Syndrome with a site in Turkey, this one is the 16th largest by planned enrollment of the 82 interventional ones that give a count, is one of 20 that started in 2026, is one of 75 with no phase, reaches primary completion later than 34 of the 40 other live ones, and was the 130th registered.

Carpal Tunnel Syndrome

591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

36 of the 130 studies in Carpal Tunnel Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Carpal Tunnel Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial aims to compare the effectiveness of low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy in patients diagnosed with mild to moderate carpal tunnel syndrome (CTS). A total of 84 eligible participants aged 18-65 years will be randomly assigned to one of three treatment groups. Group 1 (LLLT): Patients will receive low-level laser therapy 5 days a week for 3 weeks (total 15 sessions). Group 2 (Myofascial Release): Patients will receive manual myofascial release therapy 3 days a week for 5 weeks. Group 3 (Peloid Therapy): Patients will receive peloid (mud) therapy at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions). Clinical evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. The primary outcome measures are the Boston Carpal Tunnel Questionnaire (BCTSQ) and Jamar dynamometer grip strength. Secondary outcome measures include ultrasonographic median nerve cross-sectional area (CSA) and electrophysiological nerve conduction studies (EMG).

Read the detailed description

Background and Rationale: Carpal Tunnel Syndrome (CTS) is the most common peripheral nerve entrapment syndrome, resulting from the compression of the median nerve at the wrist. Conservative treatment options play a primary role in the management of mild to moderate CTS, aiming to reduce pain, alleviate symptoms, and improve functional status without immediate surgical intervention. This single-center, randomized controlled trial aims to compare the clinical and objective effectiveness of three distinct conservative modalities-low-level laser therapy (LLLT), myofascial release (MFR), and peloid therapy-routinely used in clinical practice. Study Design and Participants: A total of 84 male and female patients aged 18-65 years diagnosed with mild to moderate CTS at the Department of Physical Medicine and Rehabilitation, SBÜ Konya Beyhekim Training and Research Hospital, will be enrolled. Participants will be randomized into three intervention groups using a computer-generated randomization scheme. Intervention Groups:• Group 1 (Low-Level Laser Therapy - LLLT): Patients will receive LLLT administered by an experienced technician 5 days a week for 3 weeks (15 sessions in total). Treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light at an 860 nm wavelength, 1 kHz frequency, and 100 mW power output. The dosage will be 3.6 J/cm2, applied perpendicular to the skin over an area of approximately 15-20 cm2 for 40 seconds, with a total session duration of 120 seconds. • Group 2 (Myofascial Release - MFR): Patients will receive manual myofascial release therapy performed by an experienced physician 3 days a week for 5 weeks (15-30 minutes per session). The intervention will involve identifying tight muscle bands and trigger points in the wrist and forearm, applying direct pressure, gentle stretching, and implementing specific nerve and tendon gliding exercises. • Group 3 (Peloid Therapy): Patients will receive medical peloid therapy (sourced from Köyceğiz, Muğla, rich in organic/inorganic substances and humic acid) applied 5 days a week for 3 weeks (15 sessions in total). A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped with a plastic bag and towel for 20 minutes, followed by gentle cleansing with warm water. Outcome Measures and Evaluation Schedule: Evaluations will be performed at baseline, at the end of the treatment (15th session), and at the 12-week follow-up. • Primary Outcome Measures: Symptom severity and functional status assessed via the Boston Carpal Tunnel Questionnaire (BCTSQ), and maximum grip strength measured objectively using a Jamar dynamometer. • Secondary Outcome Measures: Ultrasonographic assessment of the median nerve cross-sectional area (CSA) at the wrist level and electrophysiological nerve conduction studies (EMG) performed at the 12-week control.

03

Conditions studied

  • Carpal Tunnel Syndrome (CTS)

Keywords

  • Mild to Moderate Carpal Tunnel Syndrome
  • Low-Level Laser Therapy (LLLT)
  • Myofascial Release (MFR)
  • Peloid Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years.
  • Diagnosis of mild or moderate Carpal Tunnel Syndrome (CTS) confirmed by electrophysiological tests (EMG).
  • Symptoms persisting for at least 3 months.
  • No prior history of surgical treatment for carpal tunnel syndrome.

Exclusion criteria

Exclusion Criteria:

  • Severe carpal tunnel syndrome detected by electrophysiological tests.
  • History of severe trauma, fracture, or surgery in the same extremity within the last 6 months.
  • Having received physical therapy (TENS, laser, exercise, etc.) or injection therapy for CTS within the last 3 months.
  • Pregnant or lactating women.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Low-Level Laser Therapy (LLLT) Group

    Patients in this group will receive low-level laser therapy (LLLT) administered 5 days a week for 3 weeks, totaling 15 sessions. The treatment will be applied using a gallium-aluminum-arsenide (GaAlAs) diode laser emitting infrared light.

    Device: Low-Level Laser Therapy

  • Active comparator
    Myofascial Release (MFR) Group

    Patients in this group will receive manual myofascial release (MFR) therapy performed 3 days a week for 5 weeks. The intervention involves identifying tight muscle bands and trigger points in the wrist and forearm, applying direct manual pressure, gentle stretching, and specific nerve and tendon gliding exercises.

    Other: Myofascial Release

  • Active comparator
    Peloid Therapy Group

    Patients in this group will receive medical peloid (mud) therapy applied 5 days a week for 3 weeks, totaling 15 sessions. A 1.5-2 cm thick layer of peloid heated to 45°C will be applied to the affected extremity, wrapped for 20 minutes, and then gently cleansed with warm water.

    Other: Peloid Therapy

Interventions

  • DeviceLow-Level Laser Therapy

    Low-level laser therapy administered 5 days a week for 3 weeks (total 15 sessions) using a GaAlAs diode laser.

  • OtherMyofascial Release

    Manual myofascial release therapy performed 3 days a week for 5 weeks, including trigger point release and neural/tendon gliding exercises.

  • OtherPeloid Therapy

    Medical peloid therapy applied at 45°C for 20 minutes, 5 days a week for 3 weeks (total 15 sessions).

06

What researchers measure

Primary outcomes

  1. Boston Carpal Tunnel Questionnaire (BCTSQ) Score

    Assessment of symptom severity and functional status using the Boston Carpal Tunnel Questionnaire (BCTSQ), which consists of a Symptom Severity Scale (11 items) and a Functional Status Scale (8 items), scored from 1 (best) to 5 (worst).

    Time frame: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

  2. Maximum Grip Strength

    Objective measurement of maximum hand grip strength evaluated using a Jamar dynamometer (recorded in kilograms or pounds).

    Time frame: Baseline, at the end of treatment (week 3 / 15th session), and at the 12-week follow-up.

Secondary outcomes

  1. Ultrasonographic Median Nerve Cross-Sectional Area (CSA)

    Assessment of the median nerve cross-sectional area (CSA) at the wrist level using high-resolution ultrasonography to evaluate structural changes and reduction in nerve swelling.

    Time frame: Baseline and at the 12-week follow-up.

  2. Electrophysiological Nerve Conduction Parameters (SNCV, SNAP, CMAP, DML)

    Evaluation of median nerve conduction characteristics, including sensory nerve conduction velocity (SNCV), sensory nerve action potential (SNAP) amplitude, compound muscle action potential (CMAP) amplitude, and distal motor latency (DML).

    Time frame: Baseline and at the 12-week follow-up.

07

Study locations

1 of 1 sites recruiting
  • University of Health Sciences, Konya Beyhekim Training and Research Hospital
    Konya, 42000, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Roll SC, Takata SC, Yao B, Kysh L, Mack WJ. Sonographic reference values for median nerve cross-sectional area: A meta-analysis of data from healthy individuals. J Diagn Med Sonogr. 2023 Sep;39(5):492-506. doi: 10.1177/87564793231176009. Epub 2023 Jun 6. PubMed 37654772 ↗
  • Jimenez-Del-Barrio S, Cadellans-Arroniz A, Ceballos-Laita L, Estebanez-de-Miguel E, Lopez-de-Celis C, Bueno-Gracia E, Perez-Bellmunt A. The effectiveness of manual therapy on pain, physical function, and nerve conduction studies in carpal tunnel syndrome patients: a systematic review and meta-analysis. Int Orthop. 2022 Feb;46(2):301-312. doi: 10.1007/s00264-021-05272-2. Epub 2021 Dec 3. PubMed 34862562 ↗
  • Savas S, Kilavuz A, Kayhan Kocak FO, Cavdar S. Comparison of Grip Strength Measurements by Widely Used Three Dynamometers in Outpatients Aged 60 Years and Over. J Clin Med. 2023 Jun 25;12(13):4260. doi: 10.3390/jcm12134260. PubMed 37445293 ↗
  • Sezgin M, Incel NA, Serhan S, Camdeviren H, As I, Erdogan C. Assessment of symptom severity and functional status in patients with carpal tunnel syndrome: reliability and functionality of the Turkish version of the Boston Questionnaire. Disabil Rehabil. 2006 Oct 30;28(20):1281-5. doi: 10.1080/09638280600621469. PubMed 17083175 ↗
  • Thomson JG. Diagnosis and treatment of carpal tunnel syndrome. Lancet Neurol. 2017 Apr;16(4):263. doi: 10.1016/S1474-4422(17)30059-5. No abstract available. PubMed 28327334 ↗
  • Wipperman J, Goerl K. Carpal Tunnel Syndrome: Diagnosis and Management. Am Fam Physician. 2016 Dec 15;94(12):993-999. PubMed 28075090 ↗
  • Padua L, Coraci D, Erra C, Pazzaglia C, Paolasso I, Loreti C, Caliandro P, Hobson-Webb LD. Carpal tunnel syndrome: clinical features, diagnosis, and management. Lancet Neurol. 2016 Nov;15(12):1273-1284. doi: 10.1016/S1474-4422(16)30231-9. Epub 2016 Oct 11. PubMed 27751557 ↗

Individual participant data

Plan to share: Yes — Prerequisites / What data will be shared:De-identified individual participant data (including demographic data, baseline and follow-up Boston Carpal Tunnel Questionnaire scores, Jamar grip strength measurements, ultrasonographic median nerve cross-sectional area [CSA] values, and electrophysiological nerve conduction parameters) underlying the results reported in the future publication will be shared.Supporting Documents:Study Protocol and Informed Consent Form will also be available upon request.Time Frame:Available beginning 3 months and ending 5 years following article publication.Access Criteria:Requests should be directed to the corresponding author via email. Data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, provided that a signed data access agreement is established.

Supporting information: Study protocol, Informed consent form

Time frame: Available beginning 3 months and ending 5 years following article publication.

Access criteria: Requests should be directed to the corresponding author via email. De-identified individual participant data will be shared with researchers whose proposed use of the data has been approved by the principal investigator and institutional ethics committee, upon the establishment of a signed data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.

Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 11 months is close to that.

Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Mar 5, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947316
Lead sponsor
Konya Beyhekim Training and Research Hospital
Responsible party
RAİKAN BÜYÜKAVCI (Associate Professor of Physical Medicine and Rehabilitation, Konya Beyhekim Training and Research Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Mar 5, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

RAİKAN BÜYÜKAVCI, MD, Prof.
Contact
rsoydemir@yahoo.com
+90-0332-224-30-00 ext. 4042
ERDİ İNCİGÜZ, M.D.
principal investigator · University of Health Sciences, Konya Beyhekim Training and Research Hospital
RAİKAN BÜYÜKAVCI, MD, Prof.
study chair · University of Health Sciences, Konya Beyhekim Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion